Tim Lowery Appointed Interim CEO of KBI and Selexis

November 9, 2022- Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.

 

For details, please see the announcement from KBI Biopharma, Inc.

https://www.kbibiopharma.com/our-resources/tim-lowery-appointed-interim-ceo-of-kbi-and-selexis

Contact details

Receive exclusive news

Are you a journalist or do you work for a publication?
Sign up and request access to exclusive news.

Request access

Receive JSR Life Sciences news on your RSS reader.

Or subscribe through Atom URL manually